Methods and compositions for inhibiting the interaction of menin with MLL proteins

Inventors: Jolanta Grembecka (Ann Arbor, MI); Tomasz Cierpicki (Ann Arbor, MI); Dmitry Borkin (Ann Arbor, MI); Jonathan Pollock (Ann Arbor, MI); Liansheng Li (San Diego, CA); Tao Wu (Carlsbad, CA); Jun Feng (San Diego, CA); Pingda Ren (San Diego, CA); Yi Liu (San Diego, CA)

Assignees: KURA ONCOLOGY, INC.; THE REGENTS OF THE UNIVERSITY OF MICHIGAN

A61K31/519 A61K31/5377 A61K31/541 A61P3/10 A61P35/02

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,588,907
App. No.: 15/578,837
Granted: Mar 17, 2020
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.

Claims (1)

1. A compound selected from the group consisting of:

Assignments (9)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2024

From: LIU, YI

To: WELLSPRING BIOSCIENCES LLC

Reel/Frame 069189/0086 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2024

From: LI, LIANSHENG

To: WELLSPRING BIOSCIENCES LLC

Reel/Frame 069324/0755 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2024